Physician profile
Patricia Ramirez
NPI 1215180203
$1,297.28
in general payments reported to CMS, 2019-2025
13 companies · $16.39 in 2025
The $16.39 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $446 · 2023: $292 · 2024: $57.70 · 2025: $16.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $606.33 | 2021-2023 | Farxiga, Breztri, Airsupra |
| Ethicon US, LLC | $190.07 | 2021-2022 | |
| Lilly USA, LLC | $112.41 | 2021-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $66.41 | 2022-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.86 | 2021-2023 | |
| Avanos Medical | $57.70 | 2024 | On-Q* Pump and Accessories |
| Abbott Laboratories | $44.04 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.35 | 2021-2022 | |
| Abbvie INC. | $30.21 | 2021 | |
| Phathom Pharmaceuticals, INC. | $25.40 | 2023 | Voquezna |
| Avion Pharmaceuticals | $24.87 | 2022 | |
| Amgen INC. | $19.24 | 2022 | |
| Integra Lifesciences Corporation | $16.39 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.